A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)

Inclusion Criteria: * Within the body weight range of 60 to 100 kilograms, inclusive (for the pivotal cohort \[Part 2\] only) * Within body mass index (BMI) range 18.0 to 30.0 kilograms per square meter (kg/m\^2), inclusive * In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), and vital signs * Females will be non-pregnant, non-lactating, and either postmenopausal (at least 12 months of non-therapy-induced amenorrhea)/surgically sterile (e.g., tubal ligation, hysterectomy) for at least 90 days prior to enrolment, or agree to remain abstinent/use a highly effective method of contraception for at least 24 weeks after study drug administration * Males will either be sterile or agree to remain abstinent/use a highly effective method of contraception for at least 24 weeks after study drug administration. Male participants will refrain from sperm donation from Check-in (Day -1) until 24 weeks following study drug administration Exclusion Criteria: * Any prior treatment with etrolizumab or other anti-integrin agents (including natalizumab, vedolizumab, and efalizumab) * Any prior treatment with anti-mucosal addressin cell adhesion molecule 1 (anti-MAdCAM-1) agents * Any prior treatment with rituximab * Received intravenous corticosteroids within 30 days prior to Screening * Use of agents that deplete B or T cells (e.g., alemtuzumab, rituximab, or visilizumab) within 12 months prior to randomization * Any prior immunosuppressive agents (including cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil) * Chronic nonsteroidal anti-inflammatory drug (NSAID) use * Use of any prescription medications/products within 14 days prior to Check in (Day -1) * History of demyelinating disease * Neurological conditions or diseases * History of cancer * History of alcoholism or drug addiction within less than (\<) 1 year prior to Screening * History of active or latent tuberculosis (TB), regardless of treatment history * History of recurrent opportunistic infections and/or history of severe disseminated viral infections * Positive for human immunodeficiency virus (HIV) antibody * Any current or recent signs or symptoms of infection * Pregnant or lactating * Hospitalized within 4 weeks prior to and during Screening * History of organ transplant * Presence of skin rash at Screening or history of other skin disorders * Tattoos, scars, chronic rashes, or sunburn in the area of the designated injection site